查看文章

The SARS-CoV-2 B. 1.617. 2 Delta variant of concern (VOC) continues to drive a sharp increase in COVID-19 cases in the UK, with a current doubling time of 3· 5–16 days, 1 consistent with previous pandemic waves during 2020–21, and a sustained increase in the reproduction number (R) to 1· 2–1· 4. 2 Daily hospital admissions and the number of patients requiring mechanical ventilation are now increasing in both England and Scotland, despite the ongoing roll-out of widespread vaccination in the UK. 1 The ChAdOx1 nCoV-19 (AZD1222, Oxford–AstraZeneca) vaccine forms the core of the UK’s vaccination programme and the global COVAXX programme. To determine B. 1.617. 2 sensitivity to AZD1222-induced neutralising antibodies (NAbs) and to compare this to our previous measurements of NAbs induced by BNT162b2 (Pfizer–BioNTech), 3 we carried out a second initial analysis of Legacy study …